|
|
|
|
|
| Clinical efficacy of Xuebijing injection in septic patients with thrombocytopenia |
| Yu Mei-xia, Wang Bing, Wang Yong-qiang, Gao Hong-mei |
| Tianjin University of Chinese Traditional Medicine |
|
|
|
|
Abstract Objective: To observe the effect of Xuebijing on inflammatory reaction, endothelium dysfunction and platelet activation in septic patients with thrombocytopenina(TCP). Methods: A total of 61 septic pactients with TCP in Intensive Care Unit of Tianjin First Central Hospital from January 2015 to January 2016 were included in this prospective study. The people who came at the same period for physical examination were taken as the normal control group (n=15). Randomly divided the 61 patients into non-Xuebijing group A (n=30) and Xuebijing group B (n=31), according to the principle of minimum distribution imbalance index with age, scores of acute physiology and chronic health evaluation Ⅱ (APACHEⅡ), platelet count three factors. Both group A and group B received conventional therapy, group B add Xuebijing injection for 7 days. The level of serum von Willebrand factor (vWF), TNF-α and plasma sCD40L were measured by enzyme linked immune sorbent assay (ELISA). The 28-day mortality of the two groups was traced. Results: ①Compared with pre-treatment, the platelet count of group A, B improved significantly post-treatment (P＜0.05 & P＜0.01), on the first and third day of admission, there was no significant difference between group A and group B (P＞0.05), on the fifth and seventh day of admission, the platelet count of group B was higher than group A (P＜0.05). ②Compared with pre-treatment, the level of vWF, TNF-α and sCD40L of group B decreased significantly post-treatment (P＜0.01 & P＜0.05), and the level of vWF, sCD40L of group A increased significantly post-treatment (P＜0.05). However, TNF-α had no significant change before and after treatment (P＞0.05). The level of vWF, TNF-α and sCD40L of group B was lower than group A after treatment (P＜0.05). ③The 28-day mortality of group A and B had no significant difference (P＞0.05). Conclusion: Xuebijing injection reduces the sepsis inflammatory reaction, protects endothelial function, downregulates platelet activation, and improves the situation of low platelet count of septic patient with TCP.
|
|
Received: 02 August 2017
|
|
Corresponding Authors:
Wang Bing, E-mail: egenbing@163.com
|
|
|
|
| ［1］Vandijck DM, Blot SI, De Waele JJ, et al. Thrombocytopenia and outcome in critic-ally ill patients with bloodstream infection［J］. Heart Lung, 2010, 39(1):21-26.
［2］Warkentin TE, Aird WC， Rand JH． Platelet, Endothelial Interactions:sepsis, HIT, and Antiphospholipid Syndrome［J］. Hematology, 2003: 497-519．
［3］耿平，夏仲芳，顾健，等. 血必净注射液对严重脓毒症患者早期高凝状态的干预作用［J］. 中国中西医结合急救杂志， 2008, 15（6）：346-348.
［4］Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 ［J］. Intensive Care Med, 2012, 39(2):165-228.
［5］Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock ［J］. N Engl J Med, 2001, 345(19):1368-1377.
［6］Angus DC, van der Poll T. Severe sepsis and septic shock ［J］. N Engl J Med, 2013, 369(21):840-851.
［7］Haznedaroglu IC, Atalar E, Ozturk MA, et al. Throm bopoietin inside the pulmonary vessels inpatients with and without pulmonaty hypertension ［J］. Platelets, 2002, 13(7):395-399.
［8］Warkentin TE, Aird WC, Rand JH. Platelet-endothelial Interactions: sepsis, HIT, and antiphospholipid Syndrome［J］. Hematology Am Soc Hematol Edue Program, 2003:497-519.
［9］王兵，王勇强，曹书华，等. 脓毒症患者血小板参数与Toll样受体4表达的关系及中西医结合治疗研究［J］. 中国危重病急救医学， 2011, 23（10）：616-620.
［10］McDonald B, Urrutia R, Yipp BG, et al. Intravascular nertrophil extracellular traps capture bacteria from the bloodstream during sepsis ［J］. Cell Host Microbe, 2012, 12(3) :324-333.
［11］Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum［J］. Semin Immunopathol, 2012, 34(1):5-30.
［12］Sun BW, Chen X. Carbon monoxide releasing molecules: new insights for anticoagulation strategy in sepsis ［J］. Cell Mol Life Sci, 2009, 66(3):365-369.
［13］Aukrust P, Damas JK. Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation［J］. J Am Coll Cardiol, 2004, 43(12) :2326-2328.
［14］Rahman M, Rller J, Zhang S, et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis ［J］. Inflamm Res, 2012, 61(6):571-579.
［15］徐俊，杨静，孟令毅，等. 脓毒症患者血清假血友病因子血管性血友病因子裂解酶水平变化的临床意义［J］. 中国急救医学, 2013, 33(5):416-419.
［16］Claus RA, Bockmeyer CL, Sossdorf M, et al. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure［J］. Curr Mol Med, 2010, 10(2): 236-248.
［17］Westbrook AM, Wei B, Hacke K, et al. The role of tumour necrosis factor-a and tumor necrosis factor receptor signalling in inflammation-associated systemic genotoxieity ［J］. Mutagenesis, 2012, 27(1):77-86.
［18］叶小玲，陶珮，陈月娥，等. 槲皮素对脓毒症大鼠肝细胞的保护作用［J］. 中国急救医学, 2015, 35(12): 1075-1078.
［19］Erbas O, Taskiran D. Sepsis-induced changes in behavioral stereotypy in rats: involvement of turnover ［J］. J Surg Res, 2014, 186(1):262-268.
［20］曹书华，高红梅，王勇强，等. 肝移植术后多器官功能障碍综合征中西医结合治疗的临床研究［J］. 中国中西医结合急救杂志， 2002, 9(5): 263-266.
［21］赵森伟，柴艳芬.血必净与低分子肝素对严重脓毒症患者凝血功能及预后的影响［J］.中华急诊医学杂志， 2011, 20(4): 405-408.
［22］苏媛，董泽华，付培荣，等. 血必净注射液对严重脓毒症患者血小板参数及凝血功能的影响［J］. 中国急救医学， 2011, 31(7):599-601.
［23］赵普宇，蔡明志，张胜利，等. 血必净注射液对发热伴血小板减少综合征的疗效分析［J］.中国急救医学， 2014, 34(10): 924-926. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
